Key result
Encapsulating AAV in protein vault nanoparticles enables successful cellular transduction despite neutralizing serum.
Why the study?
Preexisting neutralizing antibodies against adeno-associated virus limit the number of patients who can receive AAV-based gene therapies.
Does packaging AAV into protein vault nanoparticles (VAAV) improve cellular transduction in the presence of neutralizing antibodies compared to AAV alone?
Does packaging AAV into protein vault nanoparticles (VAAV) improve cellular transduction in the presence of neutralizing antibodies compared to AAV alone?
Encapsulating AAV into protein vault nanoparticles protects the virus from neutralizing antibodies and enhances cellular transduction in vitro, offering a potential strategy to overcome a major limitation of AAV gene therapy.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“My vaultAAV gene therapy invention for circumventing preexisting anti-AAV immunity has been published in ACS Synthetic Biology! This technology was the basis for my first company, Cathedral Therapeutics! [Cathedral was acquired in 2025, now I'm an advisor and board member].”
Should not yet change AAV gene therapy practice; leaves open whether vault packaging overcomes neutralizing antibodies clinically.
Although adeno-associated virus (AAV) has enjoyed enormous success as a delivery modality for gene therapy, it suffers from high prevalence of preexisting neutralizing antibodies in human populations, limiting who can receive potentially life-saving treatments. As a novel solution to this issue, we employed SpyTag-SpyCatcher molecular glue technology to facilitate packaging of AAVs inside of recombinant protein vault nanoparticles. Vaults are endogenous particles produced by mammalian cells. We therefore hypothesized that they may shield packaged molecules from neutralizing antibodies. Vaults have previously been utilized to deliver drugs and proteins into cells, but our study represents the first time anyone has packaged an entire virus inside of a vault. We showed that our vaultAAV delivery vehicle transduces cells in the presence of anti-AAV neutralizing serum. VaultAAV is positioned as a new gene therapy delivery platform with potential to overcome the neutralizing antibody problem, expanding the scope of AAV treatments.
No takes yet. Share an insight, caveat, or question.
Collins et al. (2026) studied Preexisting neutralizing antibodies to AAV gene therapy. vaultAAV (VAAV) vs. AAV alone, vault + AAV, PBS was evaluated on Cellular transduction efficiency in the presence of neutralizing serum. Encapsulation of adeno-associated virus into protein vault nanoparticles enabled successful cellular transduction in the presence of neutralizing serum, overcoming a major barrier in gene therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: